MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens
- 1 October 1996
- Vol. 24 (2) , 135-146
- https://doi.org/10.1002/(sici)1098-2396(199610)24:2<135::aid-syn5>3.0.co;2-g
Abstract
In vivo microdialysis was used in freely moving rats to determine whether the locomotor stimulant effects of dizocilpine maleate (MK-801) were related to increased dopamine (DA) release within the nucleus accumbens (N. Acc.). Each experiment began with a baseline period of at least 2 h (starting 15–20 h after insertion of concentric, removable dialysis probes), during which activity records and dialysate samples were collected every 20 min. Rats in the first experiment then were injected with MK-801 (0.125, 0.25, or 0.50 mg/kg, i.p.) or saline, and activity and extracellular levels of DA, dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were measured for a further 160 min post-injection. In a second experiment, rats were given 1.5 mg/kg d-amphetamine sulphate 40 min after receiving the same doses of MK-801, and testing was continued for 120 min. Rats in a third experiment were given low, autoreceptor-preferring doses of apomorphine hydrochloride (25 or 50 μg/kg, s.c.) or its vehicle 40 min after injection of 0.25 mg/kg MK-801 and then monitored for 120 min. MK-801 produced strong and consistent increases in locomotor activity that were augmented by amphetamine and greatly reduced by the low doses of apomorphine. MK-801 did not increase extracellular DA levels within the N. Acc. when given alone, and it failed to influence the changes in extracellular DA produced by d-amphetamine and apomorphine. MK-801 did produce consistent, dose-related increases in DOPAC and HVA that were probably not related to transmitter release. These results indicate that the increases in locomotor activity seen following MK-801 do not arise from a drug-induced increase in DA levels within the N. Acc.Keywords
This publication has 65 references indexed in Scilit:
- Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomesBrain Research, 1994
- The development of behavioral sensitization to apomorphine is blocked by MK-801European Journal of Pharmacology, 1993
- Morphine-induced potentiation of brain stimulation reward is enhanced by MK-801Brain Research, 1993
- The glycine/NMDA receptor antagonist, R‐(+)‐HA‐966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK‐801) in rodentsBritish Journal of Pharmacology, 1993
- Inhibition of nigral dopamine neurons by systemic and local apomorphine: Possible contribution of dendritic autoreceptorsNeuroscience, 1992
- Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonistBrain Research, 1990
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- Possible abuse potential of the NMDA antagonist MK-801Behavioural Brain Research, 1989
- Biochemical and behavioral effects of sigma and PCP ligandsSynapse, 1988
- Monoamine metabolites: Their relationship and lack of relationship to monoaminergic neuronal activityBiochemical Pharmacology, 1985